Gujarat-based Tatva Chintan Pharma Chem Ltd’s initial public offering (IPO) issue is set to open this week on Friday. It has received approval from the market regulator Sebi to launch its ₹500 crore IPO.
About Company
We are a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”).
Our Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. (Source: F&S Report)
In addition, our Company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. (Source: F&S Report)
As a manufacturer of specialty chemicals, we focus on application of our products which form a key ingredient to our customers’ manufacturing and industrial processes.
Important dates
| Basis of Allotment: | 26 July 2021 |
| Refunds: | 27 July 2021 |
| Credit to Demat Account: | 28 July 2021 |
| Listing Date: | 29 July 2021 |
IPO details
| IPO Open: | 16 July 2021 |
| IPO Close: | 20 July 2021 |
| IPO Size: | Approx ₹450 Crores |
| Fresh Issue: | Approx ₹225 Crores |
| Offer for Sale: | Approx ₹225 Crores |
| Face Value: | ₹10 Per Equity Share |
| Price Band: | ₹1073 to ₹1083 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
The Tatva Chintan Pharma IPO minimum market lot is 13 shares with ₹14,079 application amount. The retail investors can apply up-to 13 lots with 182 shares or ₹197,106 amount.
Company’s Financial
| Particulars (in Cr.) | Dec-20 | Mar-20 | Mar-19 | Mar-18 |
| Sales | 191.69 | 263.24 | 206.31 | 135.81 |
| Cost of Material Consumed | 102.91 | 146.16 | 118.29 | 74.10 |
| Purchases of Stock-in-Trade | 1.38 | 2.45 | 0.28 | 0.06 |
| Change in Inventories | -12.30 | -15.84 | -4.33 | -3.08 |
| Employee Benefits Expense | 17.24 | 20.53 | 16.31 | 12.27 |
| Other Expenses | 41.23 | 54.99 | 41.95 | 29.54 |
| Operating Profit | 41.23 | 54.95 | 33.81 | 22.92 |
| OPM % | 21.51% | 20.87% | 16.39% | 16.88% |
| Other Income | 3.34 | 1.38 | 0.49 | 1.48 |
| Interest | 3.16 | 3.95 | 3.63 | 2.43 |
| Depreciation | 4.96 | 4.79 | 4.02 | 2.95 |
| Profit before tax | 36.46 | 47.60 | 27.39 | 19.03 |
| Total Tax Exps | 5.31 | 9.80 | 6.84 | 6.75 |
| Net Profit | 31.14 | 37.79 | 20.54 | 12.29 |
| NPM % | 16.24% | 14.36% | 9.96% | 9.05% |
| No. of shares | 2.01 | 2.01 | 2.01 | 2.01 |
| EPS in Rs | 15.50 | 18.81 | 10.23 | 6.12 |
Intermediaries
Lead Managers:
- ICICI Securities Limited
- JM Financial Consultants Private Limited
Registrar:
- Link Intime India Private Limited
Funds Proceeds
1. Funding requirements for expansion of its Dahej Manufacturing Facility 2. Funding requirements for upgradation of its R&D facility in Vadodara 3. General corporate purposes.
Press the 🔔 icon for notifications of all new updates
